Abstract
The insulin-like growth factor (IGF) system plays a prominent role in the cancer development. The IGF-1 receptor (IGF-1R) and its associated signalling pathway is an important growth regulatory pathway that has been implicated in colorectal carcinogenesis. This study was designed to compare +3179G/A IGF1R (rs 2229765) genotype distribution in 110 colorectal cancer (CRC) patients to a group of 143 healthy controls (HCs). We also investigated serum IGF-1 levels in CRC patients and HCs in an association to genotype. IGF-1 serum levels were measured by enzyme-linked immunosorbent assay and genotyping for the +3179G/A polymorphism was performed by restriction fragment length polymorphisms–polymerase chain reaction assay. Although the genotype frequencies were comparable in both groups, higher frequency of dominant genotypes [AA/AG; 71 vs. 62 %; odds ratio (OR) = 1.52] and lower frequency of GG genotype (29 vs. 38 %) was seen in cases versus controls. When CRC patient’s group was divided into stages of disease by tumor–node–metastasis classification we observed the significantly highest frequency of AA genotype in III stage compared to controls: 22.5 versus 15 %; OR = 3.37, p = 0.026. There was a significant association between IGF-1R rs2229765 polymorphism and advanced CRC (AA/AG vs. GG: OR = 3.06, p = 0.004). The frequency of A-allele in advanced CRC was significantly higher then early CRC (52 vs. 37.7, OR = 1.78). According to genotype serum IGF-1 levels was significantly decreased in patients with GG genotype then patients with dominant genotypes. Our results showed a relationship between the +3179G>A polymorphism of the IGF-1R and serum IGF-1 with the progression of colorectal carcinoma. A dominant genetic model was established for IGF-1R rs2229765 polymorphism and CRC progression.
Similar content being viewed by others
References
Dupont J, Pierre A, Froment P, Moreau C (2003) The insulin-like growth factor axis in cell cycle progression. Horm Metab Res 35:740–750
Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332:F105–F126
Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 Receptor in cancer biology. Int J Cancer 107:873–877
LeRoith D, Roberts CT (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137
Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC (2005) The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 20:203–220
Morris JK, George LM, Wu T, Wald NJ (2006) Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. Br J Cancer 95:112–117
Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H (2009) Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. Eur J Hum Genet 17:1668–1675
Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W (2005) Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer 115:148–154
Wong HL, Delellis K, Probst-Hensch N, Koh WP, van den Berg D, Lee HP, Yu MC, Ingles SA (2005) A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with colorectal cancer risk in Singapore Chinese. Cancer Epidemiol Biomarkers Prev 14:144–151
Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD (2005) Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 14:1204–1211
Zecevic M, Amos CI, Gu X, Campos IM, Jones JS, Lynch PM, Rodriguez-Bigas MA, Frazier ML (2006) IGF1 gene polymorphism and risk for hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst 98:139–143
Reeves SG, Rich D, Meldrum CJ, Colyvas K, Kurzawski G, Suchy J, Lubinsky J, Scott RJ (2008) IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer. Int J Cancer 123:1339–1443
Wong HL, Koh WP, Probst-Hensch NM, van den Berg D, Yu MC, Ingles SA (2008) Insulin-like growth factor-1 promoter polymorphisms and colorectal cancer: a functional genomics approach. Gut 57:1090–1096
Pechlivanis S, Wagner K, Chang-Claude J, Hoffmeister M, Brenner H, Försti A (2007) Polymorphisms in the insulin like growth factor 1 and IGF binding protein 3 genes and risk of colorectal cancer. Cancer Detect Prev 31:408–416
Feik E, Baierl A, Hieger B, Fuhrlinger G, Pentz A, Stattner S, Weiss W, Pulgram T, Leeb G, Mach K, Micksche M, Gsur A (2010) Association of IGF1 and IGFBP3 polymorphisms with colorectal polyps and colorectal cancer risk. Cancer Causes Control 21:91–97
Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN, Marchand L (2012) Genetic variants, prediagnostic circulating levels of insulin-like growth factors, insulin, and glucose and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 21:810–820
LeRoy EC, Moore JH, Hu C, Martinez ML, Lance P, Duggan D, Thompson PA (2011) Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia. Hum Genet 129:503–512
Bonafe M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, Glampieri C et al (2003) Polymorphic variants of insulin-growth factor I receptor (IGF-IR) and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for evolutionary conserved mechanism of life span control. J Clin Endocrinol Metab 88:3299–3304
Albani D, Batelli S, Polito L, Vittori A, Pesaresi M, Gajo GB (2009) A polymorphic variant of the insulin-like growth factor 1 (IGF-1) receptor correlates with male longevity in the Italian population: a genetic study and evaluation of circulating IGF-1 from the “Treviso Longeva (TRELONG)” study. BMC Geriatr 9:19–26
Jessup JM, Gunderson LL, Greene FL et al (2002) Colon and rectum. In: Greene FL, Page AL, Fleming ID et al (eds) AJCC cancer staging manual, 6th edn, pp 113–124. Springer, New York
Donovan EA, Kummar S (2008) Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol/Hematol 66:91–98
Abbott AM, Bueno R, Pedrini MT, Murray JM, Smith RJ (1992) Insulin-like growth factor I receptor gene structure. J Biol Chem 267:10759–10763
Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9:753–768
Tao Y, Pinzi V, Bourhis J, Deutsch E (2007) Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nat Clin Pract Oncol 4:591–602
Allison AS, McIntyre MA, McArdle C, Habib FK (2007) The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion. Hum Pathol 38:1590–1602
Karakolev I, Stanilov N, Miteva L, Jovchev J, Dobreva Z, Stanilova S (2012) Expression of IGF-1R mRNA in colorectal carcinoma patients. Biotechnol Biotechnol Equipment 26:89–95
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852–1857
Nahta R (2012) Deciphering the role of Insulin-like growth factor-I receptor in transtuzumab resistance. Chemother Res Pract. doi: 10.1155/2012/648965
Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (2010) Germline polymorphisms in genes involved in the IGF1 predict efficacy of cetuximab in wild-type KRAS mCRC patients pathway. Clin Cancer Res 16:5591–5602
Li R, Pourpak A, Morris S (2009) Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 52:4981–5004
Andre F, Rigot V, Thimonier J, Montixi C, Parat F, Pommier G, Marvaldi J, Luis J (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 83:497–505
Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM (1998) Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res 58:4008–4014
Bauer TW, Fan F, Liu W, Johnson M, Parikh N, Parry G et al (2005) Insulin like growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 241:748–758
Chang C-H, Wang Y, Trisal P, Li R, Rossi DL, Nair A et al (2012) Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines. PLoS ONE 7(8):e44235. doi:10.1371/journal.pone.0044235
Acknowledgments
This work was supported by Grant N: 4/2012 from the Fund for Scientific and Mobile project from Faculty of Medicine at the Trakia University, Stara Zagora, Bulgaria.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stanilov, N.S., Karakolev, I.A., Deliysky, T.S. et al. Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development. Mol Biol Rep 41, 8099–8106 (2014). https://doi.org/10.1007/s11033-014-3708-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-014-3708-2